PMID- 29262660
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220321
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 61
DP  - 2017 Nov 28
TI  - Multicenter phase II study of apatinib treatment for metastatic gastric cancer 
      after failure of second-line chemotherapy.
PG  - 104552-104559
LID - 10.18632/oncotarget.21053 [doi]
AB  - Apatinib is a tyrosine kinase inhibitor and vascular endothelial growth factor 
      receptor 2 (VEGFR-2) targeted drug. A phase I clinical trial showed that this 
      agent has antitumor activity in Chinese patients with metastatic gastric cancer 
      (mGC). The aim of this study was to investigate the safety and efficacy of 
      apatinib treatment in patients with mGC. This was an open-label, multicenter, 
      single-arm study involving four institutions in China. We enrolled 42 patients 
      from March 2015 to October 2015 who experienced tumor progression after 
      second-line chemotherapy and had no other treatment options that clearly 
      conferred a survival benefit. Oral apatinib (850 mg daily) was administered 
      within 30 min of eating breakfast, lunch, or dinner on days 1 through 28 of each 
      4-week cycle. The median progression-free survival (PFS) time and median overall 
      survival (OS) time were 4.0 months (95% CI, 2.85-5.15) and 4.50 months (95% CI, 
      4.03-4.97), respectively. The disease control rate (DCR) and objective response 
      rate (ORR) were, respectively, 78.57% and 9.52% after 2 cycles and 57.14% and 
      19.05% after 4 cycles. The main adverse events (AEs) were secondary hypertension, 
      elevated aminotransferase, and hand-foot syndrome, with incidences of 35.71%, 
      45.24%, and 40.48%, respectively. The most common grade 3 to 4 AEs were secondary 
      hypertension and elevated aminotransferase, with incidences of 7.14% each. 
      Apatinib is effective and safe in heavily pretreated patients with mGC who fail 
      to respond to two or more prior chemotherapy regimens. Toxicities were tolerable 
      or could be clinically managed.
FAU - Ruan, Hanguang
AU  - Ruan H
AD  - Department of Oncology, The Third Hospital of Nanchang City, Jiangxi Province, 
      Nanchang, China.
AD  - Graduate School of Jiangxi Medical College, Nanchang University, Nanchang, China.
FAU - Dong, Junlin
AU  - Dong J
AD  - Department of Oncology, Zhuhai Peoples' Hospital of Guang Dong Province, Zhu Hai, 
      China.
FAU - Zhou, Xueliang
AU  - Zhou X
AD  - Cancer Centre, The First Affiliated Hospital of Nanchang University, Nanchang, 
      China.
FAU - Xiong, Juan
AU  - Xiong J
AD  - Department of Cancer Radiotherapy, Jiangxi Cancer Hospital of Jiangxi Province, 
      Nanchang, China.
FAU - Wang, Hua
AU  - Wang H
AD  - Department of Cancer Radiotherapy, Jiangxi Cancer Hospital of Jiangxi Province, 
      Nanchang, China.
FAU - Zhong, Xiaoming
AU  - Zhong X
AD  - Department of Cancer Radiotherapy, Jiangxi Cancer Hospital of Jiangxi Province, 
      Nanchang, China.
FAU - Cao, Xiaolong
AU  - Cao X
AD  - Department of Oncology, Panyu District Center Hospital of Guang Dong Province, 
      Guangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20170919
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC5732826
OTO - NOTNLM
OT  - Apatinib
OT  - adverse events
OT  - effective
OT  - metastatic gastric cancer (mGC)
COIS- CONFLICTS OF INTEREST The authors declare that they have no conflicts of 
      interest.
EDAT- 2017/12/22 06:00
MHDA- 2017/12/22 06:01
PMCR- 2017/11/28
CRDT- 2017/12/22 06:00
PHST- 2017/07/05 00:00 [received]
PHST- 2017/08/17 00:00 [accepted]
PHST- 2017/12/22 06:00 [entrez]
PHST- 2017/12/22 06:00 [pubmed]
PHST- 2017/12/22 06:01 [medline]
PHST- 2017/11/28 00:00 [pmc-release]
AID - 21053 [pii]
AID - 10.18632/oncotarget.21053 [doi]
PST - epublish
SO  - Oncotarget. 2017 Sep 19;8(61):104552-104559. doi: 10.18632/oncotarget.21053. 
      eCollection 2017 Nov 28.